US20100099603A1 - Lyophilized recombinant vwf formulations - Google Patents

Lyophilized recombinant vwf formulations Download PDF

Info

Publication number
US20100099603A1
US20100099603A1 US12/603,064 US60306409A US2010099603A1 US 20100099603 A1 US20100099603 A1 US 20100099603A1 US 60306409 A US60306409 A US 60306409A US 2010099603 A1 US2010099603 A1 US 2010099603A1
Authority
US
United States
Prior art keywords
formulation
concentration
rvwf
amino acid
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/603,064
Other languages
English (en)
Inventor
Kurt Schnecker
Eva Haidweger
Peter Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Baxalta Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42109151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100099603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/603,064 priority Critical patent/US20100099603A1/en
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Assigned to BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC. reassignment BAXTER HEALTHCARE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TURECEK, PETER, HAIDWEGER, EVA, SCHNECKER, KURT
Publication of US20100099603A1 publication Critical patent/US20100099603A1/en
Priority to US13/765,526 priority patent/US20130172269A1/en
Assigned to BAXALTA INCORPORATED, Baxalta GmbH reassignment BAXALTA INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAXTER INTERNATIONAL INC.
Assigned to BAXALTA INCORPORATED, Baxalta GmbH reassignment BAXALTA INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAXTER HEALTHCARE SA
Priority to US14/939,364 priority patent/US10232022B2/en
Priority to US16/258,490 priority patent/US11191813B2/en
Priority to US16/258,488 priority patent/US11197916B2/en
Priority to US17/514,906 priority patent/US20220257723A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the invention relates to formulations of lyophilized recombinant VWF and methods for making a lyophilized composition comprising recombinant VWF.
  • Von Willebrand factor is a glycoprotein circulating in plasma as a series of multimers ranging in size from about 500 to 20,000 kD.
  • Multimeric forms of VWF are composed of 250 kD polypeptide subunits linked together by disulfide bonds. VWF mediates initial platelet adhesion to the sub-endothelium of the damaged vessel wall. Only the larger multimers exhibit hemostatic activity. It is assumed that endothelial cells secrete large polymeric forms of VWF and those forms of VWF which have a low molecular weight (low molecular weight VWF) arise from proteolytic cleavage.
  • the multimers having large molecular masses are stored in the Weibel-Pallade bodies of endothelial cells and liberated upon stimulation.
  • VWF is synthesized by endothelial cells and megakaryocytes as prepro-VWF that consists to a large extent of repeated domains.
  • pro-VWF dimerizes through disulfide linkages at its C-terminal region.
  • the dimers serve as protomers for multimerization, which is governed by disulfide linkages between the free end termini.
  • the assembly to multimers is followed by the proteolytic removal of the propeptide sequence (Leyte et al., Biochem. J. 274 (1991), 257-261).
  • the primary translation product predicted from the cloned cDNA of VWF is a 2813-residue precursor polypeptide (prepro-VWF).
  • the prepro-VWF consists of a 22 amino acid signal peptide and a 741 amino acid propeptide, with the mature VWF comprising 2050 amino acids (Ruggeri Z. A., and Ware, J., FASEB J., 308-316 (1993)).
  • VWD type 3 is the most severe form in which VWF is completely missing, and VWD type 1 relates to a quantitative loss of VWF and its phenotype can be very mild.
  • VWD type 2 relates to qualitative defects of VWF and can be as severe as VWD type 3.
  • VWD type 2 has many sub forms, some being associated with the loss or the decrease of high molecular weight multimers.
  • Von Willebrand syndrome type 2a (VWS-2A) is characterized by a loss of both intermediate and large multimers.
  • VWS-2B is characterized by a loss of highest-molecular-weight multimers.
  • Other diseases and disorders related to VWF are known in the art.
  • the present invention provides formulations useful for lyophilization of recombinant VWF, resulting in a highly stable pharmaceutical composition.
  • the stable pharmaceutical composition is useful as a therapeutic agent in the treatment of individuals suffering from disorders or conditions that can benefit from the administration of recombinant VWF.
  • a stable lyophilized pharmaceutical formulation of a recombinant von Willebrand Factor comprising: (a) a rVWF; (b) one or more buffering agents; (c) one or more amino acids; (d) one or more stabilizing agents; and (e) one or more surfactants;
  • the rVWF comprising a polypeptide selected from the group consisting of: a) the amino acid sequence set out in SEQ ID NO: 3; b) a biologically active analog, fragment or variant of a); c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1; d) a biologically active analog, fragment or variant of c); and e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions;
  • the buffer is comprising of a pH buffering agent in
  • the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3.
  • the buffering agent is selected from the group consisting of citrate, glycine, histidine, HEPES, Tris and combinations of these agents.
  • the buffering agent is citrate.
  • the pH is in the range of about 6.0 to about 8.0, about 6.5 to about 7.5, or about 7.3. In another embodiment, the pH is about 7.3.
  • the aforementioned amino acid is selected from the group consisting of glycine, histidine, proline, serine, alanine and arginine.
  • the amino acid is at a concentration range of about 0.5 mM to about 300 mM.
  • the amino acid is glycine at a concentration of about 15 mM.
  • the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is citrate and the pH is about 7.3; and wherein the amino acid is glycine at a concentration of about 15 mM.
  • the aforementioned one or more stabilizing agents is selected from the group consisting of mannitol, lactose, sorbitol, xylitol, sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose and combinations of these stabilizing agents.
  • the stabilizing agents are trehalose at a concentration of about 10 g/L mM and mannitol at a concentration of about 20 g/L.
  • the aforementioned surfactant is selected from the group consisting of digitonin, Triton X-100, Triton X-114, TWEEN-20, TWEEN-80 and combinations of these surfactants.
  • the surfactant is TWEEN-80 at about 0.01 g/L.
  • the rVWF comprises amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is citrate at a concentration of about 15 mM at about pH 7.3; wherein the amino acid is glycine at a concentration of about 15 mM; wherein the stabilizing agents are trehalose at a concentration of about 10 g/L and mannitol at a concentration of about 20 g/L.; and wherein the surfactant is TWEEN-80 at about 0.1 g/L.
  • FIG. 1 shows ANCOVA analysis of pooled VWF:RCo activity in lots evaluated for stability (stored at 5° C. ⁇ 3° C.).
  • FIG. 2 shows the increase in residual moisture in rVWF FDP stored at 5° C. ⁇ 3° C.
  • FIG. 3 shows the increase in residual moisture in rVWF FDP stored at 40° C. ⁇ 2° C.
  • composition comprising
  • additional amino acids at either or both amino and carboxy termini of the given sequence. Of course, these additional amino acids should not significantly interfere with the activity of the compound.
  • composition may include additional components. These additional components should not significantly interfere with the activity of the composition.
  • pharmaceutically active means that a substance so described is determined to have activity that affects a medical parameter (e.g., but not limited to blood pressure, blood cell count, cholesterol level) or disease state (e.g., but not limited to cancer, autoimmune disorders).
  • a medical parameter e.g., but not limited to blood pressure, blood cell count, cholesterol level
  • disease state e.g., but not limited to cancer, autoimmune disorders.
  • the terms “express,” “expressing” and “expression” mean allowing or causing the information in a gene or DNA sequence to become manifest, for example, producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence.
  • a DNA sequence is expressed in or by a cell to form an “expression product” such as a protein.
  • the expression product itself e.g. the resulting protein, may also be said to be “expressed.”
  • An expression product can be characterized as intracellular, extracellular or secreted.
  • intracellular means inside a cell.
  • extracellular means outside a cell, such as a transmembrane protein.
  • a substance is “secreted” by a cell if it appears in significant measure outside the cell, from somewhere on or inside the cell.
  • polypeptide refers to a polymer composed of amino acid residues, structural variants, related naturally-occurring structural variants, and synthetic non-naturally occurring analogs thereof linked via peptide bonds. Synthetic polypeptides are prepared, for example, using an automated polypeptide synthesizer.
  • protein typically refers to large polypeptides.
  • peptide typically refers to short polypeptides.
  • fragment of a polypeptide is meant to refer to any portion of a polypeptide or protein smaller than the full-length polypeptide or protein expression product.
  • an “analog” refers to any of two or more polypeptides substantially similar in structure and having the same biological activity, but can have varying degrees of activity, to either the entire molecule, or to a fragment thereof. Analogs differ in the composition of their amino acid sequences based on one or more mutations involving substitution, deletion, insertion and/or addition of one or more amino acids for other amino acids. Substitutions can be conservative or non-conservative based on the physico-chemical or functional relatedness of the amino acid that is being replaced and the amino acid replacing it.
  • a “variant” refers to a polypeptide, protein or analog thereof that is modified to comprise additional chemical moieties not normally a part of the molecule. Such moieties may modulate the molecule's solubility, absorption, biological half-life, etc. The moieties may alternatively decrease the toxicity of the molecule and eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedure for coupling such moieties to a molecule are well known in the art. For example and without limitation, in one aspect the variant is a blood clotting factor having a chemical modification which confers a longer half-life in vivo to the protein. In various aspects, polypeptides are modified by glycosylation, pegylation, and/or polysialylation.
  • the polynucleotide and amino acid sequences of prepro-VWF are set out in SEQ ID NO:1 and SEQ ID NO:2, respectively, and are available at GenBank Accession Nos. NM — 000552 and NP — 000543, respectively.
  • the amino acid sequence corresponding to the mature VWF protein is set out in SEQ ID NO: 3 (corresponding to amino acids 764-2813 of the full length prepro-VWF amino acid sequence).
  • One form of useful rVWF has at least the property of in vivo-stabilizing, e.g. binding, of at least one Factor VIII (FVIII) molecule and having optionally a glycosylation pattern which is pharmacologically acceptable.
  • FVIII Factor VIII
  • Specific examples thereof include VWF without the A2 domain thus resistant to proteolysis (Lankhof et al., Thromb. Haemost. 77: 1008-1013, 1997), and a VWF fragment from Val 449 to Asn 730 including the glycoprotein lb-binding domain and binding sites for collagen and heparin (Pietu et al., Biochem. Biophys. Res. Commun. 164: 1339-1347, 1989).
  • the determination of the ability of a VWF to stabilize at least one FVIII molecule is, in one aspect, carried out in VWF-deficient mammals according to methods known in the state in the art.
  • the rVWF of the present invention is produced by any method known in the art.
  • One specific example is disclosed in WO86/06096 published on Oct. 23, 1986 and U.S. patent application Ser. No. 07/559,509, filed on Jul. 23, 1990, which is incorporated herein by reference with respect to the methods of producing recombinant VWF.
  • methods are known in the art for (i) the production of recombinant DNA by genetic engineering, e.g. via reverse transcription of RNA and/or amplification of DNA, (ii) introducing recombinant DNA into procaryotic or eucaryotic cells by transfection, e.g. via electroporation or microinjection, (iii) cultivating the transformed cells, e.g.
  • VWF in one aspect, made in transformed host cells using recombinant DNA techniques well known in the art. For instance, sequences coding for the polypeptide could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule is, in another aspect, synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, in still another aspect, a combination of these techniques is used.
  • the invention also provides vectors encoding polypeptides of the invention in an appropriate host.
  • the vector comprises the polynucleotide that encodes the polypeptide operatively linked to appropriate expression control sequences. Methods of effecting this operative linking, either before or after the polynucleotide is inserted into the vector, are well known.
  • Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation.
  • the resulting vector having the polynucleotide therein is used to transform an appropriate host. This transformation may be performed using methods well known in the art.
  • any of a large number of available and well-known host cells are used in the practice of this invention.
  • the selection of a particular host is dependent upon a number of factors recognized by the art, including, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all host cells are equally effective for the expression of a particular DNA sequence.
  • useful microbial host cells include, without limitation, bacteria, yeast and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.
  • Transformed host cells are cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the polypeptides are purified from culture media or the host cells themselves by methods well known in the art.
  • carbohydrate (oligosaccharide) groups are optionally attached to sites that are known to be glycosylation sites in proteins.
  • O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline.
  • X is preferably one of the 19 naturally occurring amino acids not counting proline.
  • the structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different.
  • sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, in one aspect, confers acidic properties to the glycosylated compound.
  • site(s) may be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). In other aspects, such sites are glycosylated by synthetic or semi-synthetic procedures known in the art.
  • the compounds are made by synthetic methods using, for example, solid phase synthesis techniques. Suitable techniques are well known in the art, and include those described in Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), J. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Intl. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis; U.S. Pat. No. 3,941,763; Finn et al. (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al. (1976), The Proteins (3rd ed.) 2: 257-527. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides.
  • Fragments of a polypeptide are prepared using, without limitation, enzymatic cleavage (e.g., trypsin, chymotrypsin) and also using recombinant means to generate a polypeptide fragments having a specific amino acid sequence.
  • Polypeptide fragments may be generated comprising a region of the protein having a particular activity, such as a multimerization domain or any other identifiable VWF domain known in the art.
  • Amino acid sequence analogs of a polypeptide can be substitutional, insertional, addition or deletion analogs.
  • Deletion analogs, including fragments of a polypeptide lack one or more residues of the native protein which are not essential for function or immunogenic activity. Insertional analogs involve the addition of, e.g., amino acid(s) at a non-terminal point in the polypeptide. This analog may include, for example and without limitation, insertion of an immunoreactive epitope or simply a single residue.
  • Addition analogs, including fragments of a polypeptide include the addition of one or more amino acids at either or both termini of a protein and include, for example, fusion proteins. Combinations of the aforementioned analogs are also contemplated.
  • substitutional analogs typically exchange one amino acid of the wild-type for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide without the complete loss of other functions or properties.
  • substitutions are conservative substitutions.
  • Constant amino acid substitution is substitution of an amino acid with an amino acid having a side chain or a similar chemical character.
  • Similar amino acids for making conservative substitutions include those having an acidic side chain (glutamic acid, aspartic acid); a basic side chain (arginine, lysine, histidine); a polar amide side chain (glutamine, asparagine); a hydrophobic, aliphatic side chain (leucine, isoleucine, valine, alanine, glycine); an aromatic side chain (phenylalanine, tryptophan, tyrosine); a small side chain (glycine, alanine, serine, threonine, methionine); or an aliphatic hydroxyl side chain (serine, threonine).
  • an acidic side chain glutamic acid, aspartic acid
  • a basic side chain arginine, lysine, histidine
  • a polar amide side chain glutamine, asparagine
  • a hydrophobic, aliphatic side chain leucine, isoleucine, valine
  • analogs are substantially homologous or substantially identical to the recombinant VWF from which they are derived.
  • Analogs include those which retain at least some of the biological activity of the wild-type polypeptide, e.g. blood clotting activity.
  • Polypeptide variants contemplated include, without limitation, polypeptides chemically modified by such techniques as ubiquitination, glycosylation, including polysialation, conjugation to therapeutic or diagnostic agents, labeling, covalent polymer attachment such as pegylation (derivatization with polyethylene glycol), introduction of non-hydrolyzable bonds, and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins. Variants retain the same or essentially the same binding properties of non-modified molecules of the invention.
  • Such chemical modification may include direct or indirect (e.g., via a linker) attachment of an agent to the VWF polypeptide. In the case of indirect attachment, it is contemplated that the linker may be hydrolyzable or non-hydrolyzable.
  • Preparing pegylated polypeptide analogs will in one aspect comprise the steps of (a) reacting the polypeptide with polyethylene glycol (such as a reactive ester or aldehyde derivative of PEG) under conditions whereby the binding construct polypeptide becomes attached to one or more PEG groups, and (b) obtaining the reaction product(s).
  • polyethylene glycol such as a reactive ester or aldehyde derivative of PEG
  • the optimal reaction conditions for the acylation reactions are determined based on known parameters and the desired result. For example, the larger the ratio of PEG:protein, the greater the percentage of poly-pegylated product.
  • the binding construct has a single PEG moiety at the N-terminus.
  • Polyethylene glycol may be attached to the blood clotting factor to, for example, provide a longer half-life in vivo.
  • the PEG group may be of any convenient molecular weight and is linear or branched.
  • the average molecular weight of the PEG ranges from about 2 kiloDalton (“kD”) to about 100 kDa, from about 5 kDa to about 50 kDa, or from about 5 kDa to about 10 kDa.
  • the PEG groups are attached to the blood clotting factor via acylation or reductive alkylation through a natural or engineered reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the blood clotting factor (e.g., an aldehyde, amino, or ester group) or by any other technique known in the art.
  • a natural or engineered reactive group on the PEG moiety e.g., an aldehyde, amino, thiol, or ester group
  • a reactive group on the blood clotting factor e.g., an aldehyde, amino, or ester group
  • Free reagents are optionally be separated from the rVWF-polysialic acid conjugate by, for example, ultrafiltration/diafiltration. Conjugation of rVWF with polysialic acid is achieved using glutaraldehyde as cross-linking reagent (Migneault et al., Biotechniques 37: 790-796, 2004).
  • a polypeptide of the invention is a fusion protein with a second agent which is a polypeptide.
  • the second agent which is a polypeptide is an enzyme, a growth factor, an antibody, a cytokine, a chemokine, a cell-surface receptor, the extracellular domain of a cell surface receptor, a cell adhesion molecule, or fragment or active domain of a protein described above.
  • the second agent is a blood clotting factor such as Factor VIII, Factor VII, Factor IX.
  • the fusion protein contemplated is made by chemical or recombinant techniques well-known in the art.
  • prepro-VWF and pro-VWF polypeptides will provide a therapeutic benefit in the formulations of the present invention.
  • U.S. Pat. No. 7,005,502 describes a pharmaceutical preparation comprising substantial amounts of pro-VWF that induces thrombin generation in vitro.
  • the present invention contemplates the use of recombinant biologically active fragments, variants, or analogs of the prepro-VWF (set out in SEQ ID NO:2) or pro-VWF polypeptides (amino acid residues 23 to 764 of SEQ ID NO: 2) in the formulations described herein.
  • Polynucleotides encoding fragments, variants and analogs may be readily generated by a worker of skill to encode biologically active fragments, variants, or analogs of the naturally-occurring molecule that possess the same or similar biological activity to the naturally-occurring molecule.
  • these polynucleotides are prepared using PCR techniques, digestion/ligation of DNA encoding molecule, and the like.
  • one of skill in the art will be able to generate single base changes in the DNA strand to result in an altered codon and a missense mutation, using any method known in the art, including, but not limited to site-specific mutagenesis.
  • the phrase “moderately stringent hybridization conditions” means, for example, hybridization at 42° C.
  • the formulations comprising a VWF polypeptide of the invention are lyophilized prior to administration. Lyophilization is carried out using techniques common in the art and should be optimized for the composition being developed [Tang et al., Pharm Res. 21:191-200, (2004) and Chang et al., Pharm Res. 13:243-9 (1996)].
  • a lyophilization cycle is, in one aspect, composed of three steps: freezing, primary drying, and secondary drying [A. P. Mackenzie, Phil Trans R Soc London, Ser B, Biol 278:167 (1977)].
  • freezing step the solution is cooled to initiate ice formation.
  • this step induces the crystallization of the bulking agent.
  • the ice sublimes in the primary drying stage, which is conducted by reducing chamber pressure below the vapor pressure of the ice, using a vacuum and introducing heat to promote sublimation.
  • adsorbed or bound water is removed at the secondary drying stage under reduced chamber pressure and at an elevated shelf temperature.
  • the process produces a material known as a lyophilized cake. Thereafter the cake can be reconstituted with either sterile water or suitable diluent for injection.
  • the lyophilization cycle not only determines the final physical state of excipients but also affects other parameters such as reconstitution time, appearance, stability and final moisture content.
  • the composition structure in the frozen state proceeds through several transitions (e.g., glass transitions, wettings, and crystallizations) that occur at specific temperatures and the structure may be used to understand and optimize the lyophilization process.
  • the glass transition temperature can provide information about the physical state of a solute and can be determined by differential scanning calorimetry (DSC).
  • DSC differential scanning calorimetry
  • Tg and Tg′ are an important parameter that must be taken into account when designing the lyophilization cycle. For example, Tg′ is important for primary drying.
  • the glass transition temperature provides information on the storage temperature of the final product.
  • Excipients are additives that either impart or enhance the stability and delivery of a drug product (e.g., protein). Regardless of the reason for their inclusion, excipients are an integral component of a formulation and therefore need to be safe and well tolerated by patients. For protein drugs, the choice of excipients is particularly important because they can affect both efficacy and immunogenicity of the drug. Hence, protein formulations need to be developed with appropriate selection of excipients that afford suitable stability, safety, and marketability.
  • a lyophilized formulation is, in one aspect, at least comprised of one or more of a buffer, a bulking agent, and a stabilizer.
  • a buffer In this aspect, the utility of a surfactant is evaluated and selected in cases where aggregation during the lyophilization step or during reconstitution becomes an issue.
  • An appropriate buffering agent is included to maintain the formulation within stable zones of pH during lyophilization.
  • Table A A comparison of the excipient components contemplated for liquid and lyophilized protein formulations is provided in Table A.
  • Tonicity agent/stabilizer Stabilizers include cryo and lyoprotectants Examples include Polyols, sugars and polymers Cryoprotectants protect proteins from freezing stresses Lyoprotectants stabilize proteins in the freeze-dried state Bulking agent Used to enhance product elegance and to prevent blowout Provides structural strength to the lyo cake Examples include mannitol and glycine Surfactant Employed if aggregation during the lyophilization process is an issue May serve to reduce reconstitution times Examples include polysorbate 20 and 80 Anti-oxidant Usually not employed, molecular reactions in the lyo cake are greatly retarded Metal ions/chelating agent May be included if a specific metal ion is included only as a co-factor or where the metal is required for protease activity Chelating agents are generally not needed in lyo formulations Preservative For multi-dose
  • excipients The principal challenge in developing formulations for proteins is stabilizing the product against the stresses of manufacturing, shipping and storage.
  • the role of formulation excipients is to provide stabilization against these stresses.
  • Excipients are also be employed to reduce viscosity of high concentration protein formulations in order to enable their delivery and enhance patient convenience.
  • excipients can be classified on the basis of the mechanisms by which they stabilize proteins against various chemical and physical stresses. Some excipients are used to alleviate the effects of a specific stress or to regulate a particular susceptibility of a specific protein. Other excipients have more general effects on the physical and covalent stabilities of proteins.
  • the excipients described herein are organized either by their chemical type or their functional role in formulations. Brief descriptions of the modes of stabilization are provided when discussing each excipient type.
  • the amount or range of excipient can be included in any particular formulation to achieve a biopharmaceutical formulation of the invention that promotes retention in stability of the biopharmaceutical (e.g., a protein).
  • the amount and type of a salt to be included in a biopharmaceutical formulation of the invention is selected based on the desired osmolality (i.e., isotonic, hypotonic or hypertonic) of the final solution as well as the amounts and osmolality of other components to be included in the formulation.
  • inclusion of about 5% sorbitol can achieve isotonicity while about 9% of a sucrose excipient is needed to achieve isotonicity.
  • Selection of the amount or range of concentrations of one or more excipients that can be included within a biopharmaceutical formulation of the invention has been exemplified above by reference to salts, polyols and sugars.
  • excipients including, for example, salts, amino acids, other tonicity agents, surfactants, stabilizers, bulking agents, cryoprotectants, lyoprotectants, anti-oxidants, metal ions, chelating agents and/or preservatives.
  • concentrations of the excipients described herein share an interdependency within a particular formulation.
  • concentration of a bulking agent may be lowered where, e.g., there is a high protein concentration or where, e.g., there is a high stabilizing agent concentration.
  • concentration of a stabilizing agent would be adjusted accordingly (i.e., a “tonicifying” amount of stabilizer would be used).
  • the buffer capacity of the buffering species is maximal at a pH equal to the pKa and decreases as pH increases or decreases away from this value. Ninety percent of the buffering capacity exists within one pH unit of its pKa. Buffer capacity also increases proportionally with increasing buffer concentration.
  • the buffer species and its concentration need to be defined based on its pKa and the desired formulation pH. Equally important is to ensure that the buffer is compatible with the protein and other formulation excipients, and does not catalyze any degradation reactions.
  • a third important aspect to be considered is the sensation of stinging and irritation the buffer may induce upon administration. For example, citrate is known to cause stinging upon injection (Laursen T, et al., Basic Clin Pharmacol Toxicol., 98(2): 218-21 (2006)).
  • the potential for stinging and irritation is greater for drugs that are administered via the subcutaneous (SC) or intramuscular (IM) routes, where the drug solution remains at the site for a relatively longer period of time than when administered by the IV route where the formulation gets diluted rapidly into the blood upon administration.
  • SC subcutaneous
  • IM intramuscular
  • the total amount of buffer (and any other formulation component) needs to be monitored.
  • Buffers for lyophilized formulations need additional consideration. Some buffers like sodium phosphate can crystallize out of the protein amorphous phase during freezing resulting in shifts in pH. Other common buffers such as acetate and imidazole may sublime or evaporate during the lyophilization process, thereby shifting the pH of formulation during lyophilization or after reconstitution.
  • the buffer system present in the compositions is selected to be physiologically compatible and to maintain a desired pH of the pharmaceutical formulation.
  • the pH of the solution is between pH 2.0 and pH 12.0.
  • the pH of the solution may be 2.0, 2.3, 2.5, 2.7, 3.0, 3.3, 3.5, 3.7, 4.0, 4.3, 4.5, 4.7, 5.0, 5.3, 5.5, 5.7, 6.0, 6.3, 6.5, 6.7, 7.0, 7.3, 7.5, 7.7, 8.0, 8.3, 8.5, 8.7, 9.0, 9.3, 9.5, 9.7, 10.0, 10.3, 10.5, 10.7, 11.0, 11.3, 11.5, 11.7, or 12.0.
  • the pH buffering compound may be present in any amount suitable to maintain the pH of the formulation at a predetermined level.
  • the pH buffering concentration is between 0.1 mM and 500 mM (1 M).
  • the pH buffering agent is at least 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, or 500 mM.
  • Exemplary pH buffering agents used to buffer the formulation as set out herein include, but are not limited to organic acids, glycine, histidine, glutamate, succinate, phosphate, acetate, citrate, Tris, HEPES, and amino acids or mixtures of amino acids, including, but not limited to aspartate, histidine, and glycine.
  • the buffering agent is citrate.
  • a stabilizer (or a combination of stabilizers) is added to prevent or reduce storage-induced aggregation and chemical degradation.
  • a hazy or turbid solution upon reconstitution indicates that the protein has precipitated or at least aggregated.
  • stabilizer means an excipient capable of preventing aggregation or physical degradation, including chemical degradation (for example, autolysis, deamidation, oxidation, etc.) in an aqueous state.
  • Stabilizers contemplated include, but are not limited to, sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose, mannitol, sorbitol, glycine, arginine HCL, poly-hydroxy compounds, including polysaccharides such as dextran, starch, hydroxyethyl starch, cyclodextrins, N-methyl pyrollidene, cellulose and hyaluronic acid, sodium chloride, [Carpenter et al., Develop. Biol. Standard 74:225, (1991)].
  • the stabilizer is incorporated in a concentration of about 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 700, 900, or 1000 mM.
  • mannitol and trehalose are used as stabilizing agents.
  • the formulations also include appropriate amounts of bulking and osmolarity regulating agents.
  • Bulking agents include, for example and without limitation, mannitol, glycine, sucrose, polymers such as dextran, polyvinylpyrolidone, carboxymethylcellulose, lactose, sorbitol, trehalose, or xylitol.
  • the bulking agent is mannitol.
  • the bulking agent is incorporated in a concentration of about 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 700, 900, or 1000 mM.
  • Proteins have a high propensity to interact with surfaces making them susceptible to adsorption and denaturation at air-liquid, vial-liquid, and liquid-liquid (silicone oil) interfaces. This degradation pathway has been observed to be inversely dependent on protein concentration and results in either the formation of soluble and insoluble protein aggregates or the loss of protein from solution via adsorption to surfaces. In addition to container surface adsorption, surface-induced degradation is exacerbated with physical agitation, as would be experienced during shipping and handling of the product.
  • Surfactants are commonly used in protein formulations to prevent surface-induced degradation.
  • Surfactants are amphipathic molecules with the capability of out-competing proteins for interfacial positions. Hydrophobic portions of the surfactant molecules occupy interfacial positions (e.g., air/liquid), while hydrophilic portions of the molecules remain oriented towards the bulk solvent.
  • a surface layer of surfactant molecules serve to prevent protein molecules from adsorbing at the interface. Thereby, surface-induced degradation is minimized.
  • Surfactants contemplated herein include, without limitation, fatty acid esters of sorbitan polyethoxylates, i.e. polysorbate 20 and polysorbate 80. The two differ only in the length of the aliphatic chain that imparts hydrophobic character to the molecules, C-12 and C-18, respectively. Accordingly, polysorbate-80 is more surface-active and has a lower critical micellar concentration than polysorbate-20.
  • Detergents can also affect the thermodynamic conformational stability of proteins.
  • the effects of a given detergent excipient will be protein specific.
  • polysorbates have been shown to reduce the stability of some proteins and increase the stability of others.
  • Detergent destabilization of proteins can be rationalized in terms of the hydrophobic tails of the detergent molecules that can engage in specific binding with partially or wholly unfolded protein states. These types of interactions could cause a shift in the conformational equilibrium towards the more expanded protein states (i.e. increasing the exposure of hydrophobic portions of the protein molecule in complement to binding polysorbate).
  • detergent binding to the native state may stabilize that conformation.
  • polysorbates are inherently susceptible to oxidative degradation. Often, as raw materials, they contain sufficient quantities of peroxides to cause oxidation of protein residue side-chains, especially methionine. The potential for oxidative damage arising from the addition of stabilizer emphasizes the point that the lowest effective concentrations of excipients should be used in formulations. For surfactants, the effective concentration for a given protein will depend on the mechanism of stabilization.
  • exemplary surfactants include, without limitation, anionic, cationic, nonionic, zwitterionic, and amphoteric surfactants including surfactants derived from naturally-occurring amino acids.
  • Anionic surfactants include, but are not limited to, sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate, chenodeoxycholic acid, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, and glycodeoxycholic acid sodium salt.
  • Cationic surfactants include, but are not limited to, benzalkonium chloride or benzethonium chloride, cetylpyridinium chloride monohydrate, and hexadecyltrimethylammonium bromide.
  • Zwitterionic surfactants include, but are not limited to, CHAPS, CHAPSO, SB3-10, and SB3-12.
  • Non-ionic surfactants include, but are not limited to, digitonin, Triton X-100, Triton X-114, TWEEN-20, and TWEEN-80.
  • Surfactants also include, but are not limited to lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 40, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, soy lecithin and other phospholipids such as dioleyl phosphatidyl choline (DOPC), dimyristoylphosphatidyl glycerol (DMPG), dimyristoylphosphatidyl choline (DMPC), and (dioleyl phosphatidyl glycerol) DOPG; sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose.
  • DOPC dioleyl phosphatidyl choline
  • DMPG dimyristoylphosphatidyl glycerol
  • DMPC dimyristoylphosphatidyl choline
  • DOPG dimyristoylphosphatidyl choline
  • DOPG sucrose fatty acid este
  • compositions comprising these surfactants, either individually or as a mixture in different ratios, are therefore further provided.
  • the surfactant is TWEEN-80.
  • the surfactant is incorporated in a concentration of about 0.01 to about 0.5 g/L.
  • the surfactant concentration is 0.005, 0.01, 0.02, 0.03, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 g/L.
  • Salts are often added to increase the ionic strength of the formulation, which can be important for protein solubility, physical stability, and isotonicity.
  • Salts can affect the physical stability of proteins in a variety of ways. Ions can stabilize the native state of proteins by binding to charged residues on the protein's surface. Alternatively, salts can stabilize the denatured state by binding to peptide groups along the protein backbone (—CONH—). Salts can also stabilize the protein native conformation by shielding repulsive electrostatic interactions between residues within a protein molecule. Salts in protein formulations can also shield attractive electrostatic interactions between protein molecules that can lead to protein aggregation and insolubility. In formulations provided, the salt concentration is between 0.1, 1, 10, 20, 30, 40, 50, 80, 100, 120, 150, 200, 300, and 500 mM.
  • Amino acids have found versatile use in protein formulations as buffers, bulking agents, stabilizers and antioxidants.
  • histidine and glutamic acid are employed to buffer protein formulations in the pH range of 5.5-6.5 and 4.0-5.5 respectively.
  • Glutamic acid is particularly useful in such cases.
  • Histidine is commonly found in marketed protein formulations, and this amino acid provides an alternative to citrate, a buffer known to sting upon injection.
  • histidine has also been reported to have a stabilizing effect, with respect to aggregation when used at high concentrations in both liquid and lyophilized presentations (Chen B, et al., Pharm Res., 20(12): 1952-60 (2003)). Histidine was also observed by others to reduce the viscosity of a high protein concentration formulation. However, in the same study, the authors observed increased aggregation and discoloration in histidine containing formulations during freeze-thaw studies of the antibody in stainless steel containers. Another note of caution with histidine is that it undergoes photo-oxidation in the presence of metal ions (Tomita M, et al., Biochemistry, 8(12): 5149-60 (1969)). The use of methionine as an antioxidant in formulations appears promising; it has been observed to be effective against a number of oxidative stresses (Lam X M, et al., J Pharm Sci., 86(11): 1250-5 (1997)).
  • formulations which include one or more of the amino acids glycine, proline, serine, arginine and alanine have been shown to stabilize proteins by the mechanism of preferential exclusion.
  • Glycine is also a commonly used bulking agent in lyophilized formulations.
  • Arginine has been shown to be an effective agent in inhibiting aggregation and has been used in both liquid and lyophilized formulations.
  • the amino acid concentration is between 0.1, 1, 10, 20, 30, 40, 50, 80, 100, 120, 150, 200, 300, and 500 mM.
  • the amino acid is glycine.
  • Oxidation of protein residues arises from a number of different sources. Beyond the addition of specific antioxidants, the prevention of oxidative protein damage involves the careful control of a number of factors throughout the manufacturing process and storage of the product such as atmospheric oxygen, temperature, light exposure, and chemical contamination.
  • the invention therefore contemplates the use of the pharmaceutical antioxidants including, without limitation, reducing agents, oxygen/free-radical scavengers, or chelating agents.
  • Antioxidants in therapeutic protein formulations are, in one aspect, water-soluble and remain active throughout the product shelf-life. Reducing agents and oxygen/free-radical scavengers work by ablating active oxygen species in solution.
  • Chelating agents such as EDTA are effective by binding trace metal contaminants that promote free-radical formation. For example, EDTA was utilized in the liquid formulation of acidic fibroblast growth factor to inhibit the metal ion catalyzed oxidation of cysteine residues.
  • transition metal ions are undesired in protein formulations because they can catalyze physical and chemical degradation reactions in proteins.
  • specific metal ions are included in formulations when they are co-factors to proteins and in suspension formulations of proteins where they form coordination complexes (e.g., zinc suspension of insulin).
  • magnesium ions (10-120 mM) has been proposed to inhibit the isomerization of aspartic acid to isoaspartic acid (WO 2004039337).
  • rhDNase human deoxyribonuclease
  • Pulmozyme® human deoxyribonuclease
  • Factor VIII Factor VIII.
  • Ca +2 ions up to 100 mM
  • increases the stability of the enzyme through a specific binding site Choen B, et al., J Pharm Sci., 88(4): 477-82 (1999)
  • removal of calcium ions from the solution with EGTA caused an increase in deamidation and aggregation.
  • this effect was observed only with Ca +2 ions; other divalent cations Mg +2 , Mn +2 and Zn +2 were observed to destabilize rhDNase. Similar effects were observed in Factor VIII.
  • Ca +2 and Sr +2 ions stabilized the protein while others like Mg +2, Mn +2 and Zn +2 , Cu +2 and Fe +2 destabilized the enzyme (Fatouros, A., et al., Int. J. Pharm., 155, 121-131 (1997).
  • Factor VIII a significant increase in aggregation rate was observed in the presence of Al +3 ions (Derrick T S, et al., J. Pharm. Sci., 93(10): 2549-57 (2004)).
  • the authors note that other excipients like buffer salts are often contaminated with Al +3 ions and illustrate the need to use excipients of appropriate quality in formulated products.
  • Preservatives are necessary when developing multi-use parenteral formulations that involve more than one extraction from the same container. Their primary function is to inhibit microbial growth and ensure product sterility throughout the shelf-life or term of use of the drug product. Commonly used preservatives include, without limitation, benzyl alcohol, phenol and m-cresol. Although preservatives have a long history of use, the development of protein formulations that includes preservatives can be challenging. Preservatives almost always have a destabilizing effect (aggregation) on proteins, and this has become a major factor in limiting their use in multi-dose protein formulations (Roy S, et al., J Pharm Sci., 94(2): 382-96 (2005)).
  • hGH human growth hormone
  • the effective preservative concentration in the drug product must be optimized. This requires testing a given preservative in the dosage form with concentration ranges that confer anti-microbial effectiveness without compromising protein stability. For example, three preservatives were successfully screened in the development of a liquid formulation for interleukin-1 receptor (Type I), using differential scanning calorimetry (DSC). The preservatives were rank ordered based on their impact on stability at concentrations commonly used in marketed products (Remmele R L Jr., et al., Pharm Res., 15(2): 200-8 (1998)).
  • preservatives can cause injection site reactions, which is another factor that needs consideration when choosing a preservative.
  • pain perception was observed to be lower in formulations containing phenol and benzyl alcohol as compared to a formulation containing m-cresol (Kappelgaard A. M., Horm Res. 62 Suppl 3:98-103 (2004)).
  • benzyl alcohol possesses anesthetic properties (Minogue S C, and Sun D A., Anesth Analg., 100(3): 683-6 (2005)).
  • preservatives provide a benefit that outweighs any side effects.
  • the present invention further contemplates methods for the preparation of pharmaceutical formulations.
  • the present methods further comprise one or more of the following steps: adding a stabilizing agent as described herein to said mixture prior to lyophilizing, adding at least one agent selected from a bulking agent, an osmolarity regulating agent, and a surfactant, each of which as described herein, to said mixture prior to lyophilization.
  • the lyophilized material may be reconstituted as an aqueous solution.
  • aqueous carriers e.g., sterile water for injection, water with preservatives for multi dose use, or water with appropriate amounts of surfactants (for example, an aqueous suspension that contains the active compound in admixture with excipients suitable for the manufacture of aqueous suspensions).
  • excipients are suspending agents, for example and without limitation, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents are a naturally-occurring phosphatide, for example and without limitation, lecithin, or condensation products of an alkylene oxide with fatty acids, for example and without limitation, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example and without limitation, heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example and without limitation, polyethylene sorbitan monooleate.
  • compositions comprises one or more pharmaceutically acceptable carriers.
  • pharmaceutically acceptable carriers include any and all clinically useful solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like, including those agents disclosed above.
  • compositions are administered orally, topically, transdermally, parenterally, by inhalation spray, vaginally, rectally, or by intracranial injection.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracisternal injection, or infusion techniques. Administration by intravenous, intradermal, intramusclar, intramammary, intraperitoneal, intrathecal, retrobulbar, intrapulmonary injection and or surgical implantation at a particular site is contemplated as well.
  • compositions are essentially free of pyrogens, as well as other impurities that could be harmful to the recipient.
  • compositions are carried out with the dose levels and pattern being selected by the treating physician.
  • the appropriate dosage depends on the type of disease to be treated, as defined above, the severity and course of the disease, whether drug is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the drug, and the discretion of the attending physician.
  • kits which comprise one or more lyophilized compositions packaged in a manner which facilitates their use for administration to subjects.
  • a kit includes pharmaceutical formulation described herein (e.g., a composition comprising a therapeutic protein or peptide), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method.
  • the pharmaceutical formulation is packaged in the container such that the amount of headspace in the container (e.g., the amount of air between the liquid formulation and the top of the container) is very small.
  • the amount of headspace is negligible (i.e., almost none).
  • the kit contains a first container having a therapeutic protein or peptide composition and a second container having a physiologically acceptable reconstitution solution for the composition.
  • the pharmaceutical formulation is packaged in a unit dosage form.
  • the kit may further include a device suitable for administering the pharmaceutical formulation according to a specific route of administration.
  • the kit contains a label that describes use of the pharmaceutical formulations.
  • a typical dose of a recombinant VWF of the present invention is approximately 50 U/kg, equal to 500 ⁇ g/kg.
  • formulations of the invention are administered by an initial bolus followed by a continuous infusion to maintain therapeutic circulating levels of drug product.
  • the inventive compound is administered as a one-time dose.
  • Those of ordinary skill in the art will readily optimize effective dosages and administration regimens as determined by good medical practice and the clinical condition of the individual patient. The frequency of dosing depends on the pharmacokinetic parameters of the agents and the route of administration.
  • the optimal pharmaceutical formulation is determined by one skilled in the art depending upon the route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, the disclosure of which is hereby incorporated by reference.
  • Such formulations influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agents.
  • a suitable dose is calculated according to body weight, body surface area or organ size.
  • Appropriate dosages may be ascertained through use of established assays for determining blood level dosages in conjunction with appropriate dose-response data.
  • the final dosage regimen is determined by the attending physician, considering various factors which modify the action of drugs, e.g. the drug's specific activity, the severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.
  • “Visible aggregates,” in most cases, are gelatinous fibers ranging in size from about 100 nm to 1-2 cm.
  • Trehalose provided the best results (i.e., the least amount of aggregation).
  • Lyophilization experiments were designed to assess the ability o various formulations to allow the formation of a lyo-cake which dissolves in less than 10 minutes and results in a clear solution. An accelerated stability study was also performed to demonstrate that no significant loss of biological activity.
  • the formulations shown in Table 6 below were lyophilized with a nitrogen lyophilizer TS20002 according to the manufacturer's instructions. The total time for lyophilization was approximately 72 hours. Each of the formulations below also contained 20 g/L Mannitol and 0.1 g/L Tween-80.
  • VWF:Ag corresponds to the amount of VWF which can be detected in an VWF-specific ELISA using polyclonal anti-VWF antibody
  • VWF:RCo corresponds to the amount of VWF which causes agglutination of stabilized platelets in the presence of ristocetin.
  • Samples were stored at 40° C. Assuming applicability of the Arrhenius equation, one month stability at 40° C. is equivalent to approximately one year at 4° C. The results of the stability experiments are shown in Table 8 and Table 9 below.
  • the standard deviation for the ELISA is in the range of 10-20%. The results above indicate that all of the formulations tested provide good stability over 8 weeks at 40o C.
  • rVWF is stable in all citrate buffer systems tested, independent of buffer molarity and amino acids added. rVWF remains stable for at least 13 months even when stored at 40° C.
  • the potency determination using the VWF:RCo activity assay shows good intermediate precision with CV values below 20%.
  • rVWF a formulation was proposed for rVWF including 15 mM citrate (Na 3 Citrate ⁇ 2H 2 O), 15 mM glycine, 10 g/L Trehalose, 20 g/L Mannitol, 0.1 g/L Tween-80, pH 7.3.
  • the stability protocol including a description of the stability-indicating assays and stability-acceptance criteria, can be found in Table 10 which also contains information related to the rVWF FDP lots evaluated in the stability studies.
  • rVWF#4FC 0, 1, 2, 3, 6, 9, 12, 18, 24, (30) months 40° C. rVWF#4FC 0, 1, 2, 3, 6, 9 months 5° C. ⁇ 3° C. rVWF#5FC 0, 1, 2, 3, 6, 9, 12, 18, (24, 30) months 40° C. rVWF#5FC 0, 1, 2, 36, 9 months 5° C. + 3° C. rVWF#6FC 0, 1, 2, 3, 6, 9, 12, (18, 24, 30) months 40° C. rVWF#6FC 0, 1, 2, 3, 6, 9 months 5° C. ⁇ 3° C. rVWF#7FC 0, 1 ,2, 3, 6, 9, 12, (18, 24, 30) months 40° C. rVWF#7FC 0, 1, 2, 3, 6, 9 months
  • the rVWF FDP stability data presented is comprised of the following:
  • the rVWF FDP manufactured at a large-scale exhibited similar stability characteristics to the rVWF FDP lots manufactured at an experimental scale. These rVWF FDP lots maintained VWF:RCo activity for up to 24 months of storage at 5° C. ⁇ 3° C. There was no change in the VWF multimer pattern in samples of the large-scale lots currently on stability, even after 6 months of storage at 30° C. ⁇ 2° C. or 9 months storage at 40° C. ⁇ 2° C.
  • Table 11 shows results for VWF:RCo, VWF:Ag and VWF multimer pattern of the batches rVWF#4FC, rVWF#5FC, rVWF#6FC and rVWF#7FC stored under stress condition at 40° C. ⁇ 2° C.
  • the results indicate stability at elevated temperature storage conditions for 9 months which can be extrapolated into a shelf life of more than 3 years at ambient temperatures or even more under refrigerated conditions.
  • VWF RCo Activity 70-150 107 119 120 116 132 134 [U/ml] 1) VWF: Ag Report 94 86 84 91 90 79 ELISA (U/ml) result VWF multimer Report 20 20 18 19 20 19 analysis result Stability Data for rVWF#6FC at 40° C. ⁇ 2° C.
  • VWF RCo Activity 70-150 118 111 126 129 130 119 [U/ml]
  • VWF Ag Report 85 95 86.3 73.5 80.8 70.3 ELISA (U/ml) result VWF multimer Report 20 19 20 20 20 20 n.t. analysis result Stability Data for rVWF#7FC at 40° C. ⁇ 2° C.
  • VWF RCo Activity 70-150 111 115 122 105 99 112 [U/ml] 1) VWF: Ag Report 87.3 85.3 77.5 68.8 75 73.8 ELISA (U/ml) result VWF multimer Report 21 20 20 19 19 19 analysis result
  • the lower confidence interval for the mean curve decreases to 80% of initial activity at 51 months (80% is also the maximum difference between estimated potency and stated potency for Human von Willebrand Factor in Ph.Eur).
  • the pooled worse case slope shows a decrease of 0.0344 U VWF:RCo per month.
  • This comparison shows that stability characteristics of the rVWF FDP, specifically the VWF:RCo activity, did not change as a result of the changes in the production process.
  • the above extrapolation supports the extension of the provisional shelf life of rVWF FDP to 24 months when stored at the recommended storage temperature.
  • the transfer of moisture from the stopper to the lyophilized product is dependent on the stopper material and is influenced by the residual moisture of the stopper after sterilization, the humidity at which the sample is stored and the intrinsic moisture transfer rate of the stopper.
  • Lots stored at the elevated temperature condition 40° C. ⁇ 2° C. also showed a comparable increase in residual moisture over 9 months ( FIG. 3 ).
  • FIG. 3 shows the extrapolation of the worse case pooled slope up to 24 months.
  • the recommended storage condition for the rVWF FDP is 5° C. ⁇ 3° C.
  • a provisional shelf life of 24 months for the rVWF FDP is therefore proposed when stored at the recommended storage condition.
  • the shelf life for the rVWF FDP lots likely can be further extended based on additional data to be generated for longer storage periods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
US12/603,064 2007-12-28 2009-10-21 Lyophilized recombinant vwf formulations Abandoned US20100099603A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/603,064 US20100099603A1 (en) 2008-10-21 2009-10-21 Lyophilized recombinant vwf formulations
US13/765,526 US20130172269A1 (en) 2008-10-21 2013-02-12 Lyophilized recombinant vwf formulations
US14/939,364 US10232022B2 (en) 2008-10-21 2015-11-12 Lyophilized recombinant VWF formulations
US16/258,488 US11197916B2 (en) 2007-12-28 2019-01-25 Lyophilized recombinant VWF formulations
US16/258,490 US11191813B2 (en) 2007-12-28 2019-01-25 Lyophilized recombinant VWF formulations
US17/514,906 US20220257723A1 (en) 2007-12-28 2021-10-29 Lyophilized recombinant vwf formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10727308P 2008-10-21 2008-10-21
US12/603,064 US20100099603A1 (en) 2008-10-21 2009-10-21 Lyophilized recombinant vwf formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/693,078 Continuation US11191837B2 (en) 2007-12-28 2015-04-22 Recombinant VWF formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/765,526 Division US20130172269A1 (en) 2008-10-21 2013-02-12 Lyophilized recombinant vwf formulations
US14/939,364 Continuation US10232022B2 (en) 2007-12-28 2015-11-12 Lyophilized recombinant VWF formulations

Publications (1)

Publication Number Publication Date
US20100099603A1 true US20100099603A1 (en) 2010-04-22

Family

ID=42109151

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/603,064 Abandoned US20100099603A1 (en) 2007-12-28 2009-10-21 Lyophilized recombinant vwf formulations
US13/765,526 Abandoned US20130172269A1 (en) 2008-10-21 2013-02-12 Lyophilized recombinant vwf formulations
US14/939,364 Active US10232022B2 (en) 2007-12-28 2015-11-12 Lyophilized recombinant VWF formulations
US16/258,490 Active US11191813B2 (en) 2007-12-28 2019-01-25 Lyophilized recombinant VWF formulations

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/765,526 Abandoned US20130172269A1 (en) 2008-10-21 2013-02-12 Lyophilized recombinant vwf formulations
US14/939,364 Active US10232022B2 (en) 2007-12-28 2015-11-12 Lyophilized recombinant VWF formulations
US16/258,490 Active US11191813B2 (en) 2007-12-28 2019-01-25 Lyophilized recombinant VWF formulations

Country Status (21)

Country Link
US (4) US20100099603A1 (de)
EP (2) EP2601932A1 (de)
JP (6) JP5781931B2 (de)
KR (2) KR101953494B1 (de)
CN (2) CN102387784B (de)
AR (2) AR074054A1 (de)
AU (1) AU2009307648C1 (de)
BR (1) BRPI0919693A2 (de)
CA (1) CA2740919A1 (de)
CY (1) CY1113869T1 (de)
DK (1) DK2349314T3 (de)
ES (1) ES2409032T3 (de)
HR (1) HRP20130414T1 (de)
MX (1) MX2011004247A (de)
NZ (1) NZ592704A (de)
PL (1) PL2349314T3 (de)
PT (1) PT2349314E (de)
SI (1) SI2349314T1 (de)
SM (1) SMT201300093B (de)
TW (3) TWI508735B (de)
WO (1) WO2010048275A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012171031A1 (en) * 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
US10208106B2 (en) 2010-05-26 2019-02-19 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US11136350B2 (en) 2010-05-26 2021-10-05 Takeda Pharmaceutical Company Limited Method to produce an immunoglobulin preparation with improved yield
US11529395B2 (en) 2017-07-07 2022-12-20 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI508735B (zh) * 2008-10-21 2015-11-21 巴克斯特國際公司 凍乾的重組ｖｗｆ調配物
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
EP2698162A1 (de) 2012-08-15 2014-02-19 Credentis AG Verfahren zur Herstellung einer Zusammensetzung zur Behandlung einer Zahnläsion
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
ES2751607T3 (es) 2014-06-13 2020-04-01 Csl Ltd Producción mejorada de factor de von Willebrand recombinante en un biorreactor
JP6866296B2 (ja) * 2015-02-27 2021-04-28 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System ポリペプチド治療及びその使用
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
CN111565741A (zh) 2017-07-07 2020-08-21 百深公司 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者
CN110997015A (zh) 2017-08-23 2020-04-10 德国杰特贝林生物制品有限公司 用于von Willebrand因子的病毒过滤的方法
US10934340B2 (en) 2018-03-21 2021-03-02 Baxalta Incorporated Separation of VWF and VWF propeptide by chromatographic methods
JP7496826B2 (ja) 2018-09-10 2024-06-07 ラング セラピューティクス，エルエルシー Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
US20200261546A1 (en) 2019-02-01 2020-08-20 Baxalta Incorporated METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
EP4028046B1 (de) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Verfahren zur behandlung im zusammenhang mit komplexen des von-willebrand-faktors und komplement c1q
EP4100048A1 (de) 2020-02-04 2022-12-14 Takeda Pharmaceutical Company Limited Behandlung von menorrhagie bei patientinnen mit schwerer von-willebrand-krankheit durch verabreichung von rekombinantem vwf
CN111789867B (zh) * 2020-08-27 2022-01-11 中国人民解放军军事科学院军事医学研究院 一种适用于提高血浆干粉功能的适配液
JP7371208B2 (ja) * 2022-01-19 2023-10-30 Ｋｍバイオロジクス株式会社 ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子含有製剤
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
WO1993000107A1 (en) * 1991-06-20 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5869617A (en) * 1994-10-04 1999-02-09 Immuno Aktiengesellschaft High and low molecular weight fractions of von Willebrand Factor and preparations of same
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US6040143A (en) * 1996-07-19 2000-03-21 The Regents Of The University Of Michigan DNA encoding von Willebrand factor and methods of use
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6465624B1 (en) * 1997-02-27 2002-10-15 Baxter Aktiengesellschaft Purification of von-Willebrand factor by cation exchanger chromatography
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6649386B2 (en) * 1995-01-19 2003-11-18 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US7005502B1 (en) * 1997-05-28 2006-02-28 Baxter Aktiengesellschaft Pharmaceutical preparation comprising vWF propeptide
US7049336B2 (en) * 2000-08-31 2006-05-23 Max-Delbruck-Centrum Fur Molekularc Medizin Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
US20060160948A1 (en) * 2004-12-27 2006-07-20 Friedrich Scheiflinger Polymer-von Willebrand factor-conjugates
US7166709B2 (en) * 2000-04-18 2007-01-23 Octapharma Ag Haemostatically active preparation containing vWF and method for the production thereof
US20070021338A1 (en) * 2003-12-19 2007-01-25 Novo Nordisk Healthcare A/G Stabilised compositions of Factor VII
US7220836B2 (en) * 1995-01-19 2007-05-22 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US20090088370A1 (en) * 2005-03-29 2009-04-02 Octapharma Ag Method for Improved Isolation of Recombinantly Produced Proteins
US20090148406A1 (en) * 2005-07-02 2009-06-11 Arecor Limited Stable Aqueous Systems Comprising Proteins
US20090192076A1 (en) * 2007-12-28 2009-07-30 Baxter International Inc. Recombinant vwf formulations
US20100028372A1 (en) * 2007-01-11 2010-02-04 Jan Jezek Stabilization of aqueous compositions of proteins with displacement buffers
US7659247B2 (en) * 2004-09-14 2010-02-09 Biotest Ag Production of a von Willebrand factor preparation having a high specific activity
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100137211A1 (en) * 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
US7833766B2 (en) * 2006-02-07 2010-11-16 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
US20100305305A1 (en) * 2007-08-30 2010-12-02 Lfb-Biotechnologies Method for purifying factor viii and von willebrand factor
US7888476B2 (en) * 2004-08-16 2011-02-15 Laboratoire Francais Du Fractionnement Et Des Process for the preparation of a von Willebrand (FvW) factor concentrate by chromatography and a FvW concentrate thus obtainable
US20110092681A1 (en) * 2009-08-20 2011-04-21 Baxter International Inc. Purification of VWF for Increased Removal of Non-Lipid Enveloped Viruses
US7932355B2 (en) * 2003-10-23 2011-04-26 Lfb Sa Virally-safe factor VIII with a low content of higher multimers
US20110112023A1 (en) * 2008-07-10 2011-05-12 Gerhard Dickneite Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
US7960182B2 (en) * 2005-05-09 2011-06-14 Prometic Biosciences Ltd. Affinity adsorbents for Factor VIII and von Willebrand's Factor
US20120027740A1 (en) * 2009-02-05 2012-02-02 Pierre Philippart Method and means for producing tissues and tissues obtained
US20120027743A1 (en) * 2008-11-03 2012-02-02 Bayer Healthcare Llc Method for the Treatment of Hemophilia
US8187799B2 (en) * 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5201033A (en) 1990-01-17 1993-04-06 International Business Machines Corporation Method for controlling cursor movements on certain computer workstations
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US20010046487A1 (en) 1994-12-30 2001-11-29 Roser Bruce J. Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
US20020019036A1 (en) 1996-12-13 2002-02-14 Hans-Peter Schwarz Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
IL154880A0 (en) 2000-10-02 2003-10-31 Novo Nordisk As Method for the production of vitamin k-dependent proteins
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US7559509B1 (en) 2007-02-12 2009-07-14 Thomas C. Taylor Large cryogenic tank logistics for in-space vehicles
CA2690218C (en) * 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
TWI508735B (zh) * 2008-10-21 2015-11-21 巴克斯特國際公司 凍乾的重組ｖｗｆ調配物

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
WO1993000107A1 (en) * 1991-06-20 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
US5539086A (en) * 1991-06-20 1996-07-23 Rh one-Poulenc Rorer Pharmaceuticals Inc. Therapeutic fragments of von Willebrand factor
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5869617A (en) * 1994-10-04 1999-02-09 Immuno Aktiengesellschaft High and low molecular weight fractions of von Willebrand Factor and preparations of same
US5872099A (en) * 1994-10-04 1999-02-16 Immuno Aktiengesellschaft High molecular and low molecular fractions of von Willebrand Factor
US5892005A (en) * 1994-10-04 1999-04-06 Immuno Aktiengesellschaft High molecular and low molecular fractions of von willebrand factor
US6649386B2 (en) * 1995-01-19 2003-11-18 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7220836B2 (en) * 1995-01-19 2007-05-22 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244825B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition trehalose
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6040143A (en) * 1996-07-19 2000-03-21 The Regents Of The University Of Michigan DNA encoding von Willebrand factor and methods of use
US6465624B1 (en) * 1997-02-27 2002-10-15 Baxter Aktiengesellschaft Purification of von-Willebrand factor by cation exchanger chromatography
US7005502B1 (en) * 1997-05-28 2006-02-28 Baxter Aktiengesellschaft Pharmaceutical preparation comprising vWF propeptide
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US7166709B2 (en) * 2000-04-18 2007-01-23 Octapharma Ag Haemostatically active preparation containing vWF and method for the production thereof
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US7049336B2 (en) * 2000-08-31 2006-05-23 Max-Delbruck-Centrum Fur Molekularc Medizin Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7932355B2 (en) * 2003-10-23 2011-04-26 Lfb Sa Virally-safe factor VIII with a low content of higher multimers
US20070021338A1 (en) * 2003-12-19 2007-01-25 Novo Nordisk Healthcare A/G Stabilised compositions of Factor VII
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US7888476B2 (en) * 2004-08-16 2011-02-15 Laboratoire Francais Du Fractionnement Et Des Process for the preparation of a von Willebrand (FvW) factor concentrate by chromatography and a FvW concentrate thus obtainable
US7659247B2 (en) * 2004-09-14 2010-02-09 Biotest Ag Production of a von Willebrand factor preparation having a high specific activity
US20060160948A1 (en) * 2004-12-27 2006-07-20 Friedrich Scheiflinger Polymer-von Willebrand factor-conjugates
US20090088370A1 (en) * 2005-03-29 2009-04-02 Octapharma Ag Method for Improved Isolation of Recombinantly Produced Proteins
US7960182B2 (en) * 2005-05-09 2011-06-14 Prometic Biosciences Ltd. Affinity adsorbents for Factor VIII and von Willebrand's Factor
US20090148406A1 (en) * 2005-07-02 2009-06-11 Arecor Limited Stable Aqueous Systems Comprising Proteins
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
US7833766B2 (en) * 2006-02-07 2010-11-16 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
US20100028372A1 (en) * 2007-01-11 2010-02-04 Jan Jezek Stabilization of aqueous compositions of proteins with displacement buffers
US20100137211A1 (en) * 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
US8187799B2 (en) * 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US20100305305A1 (en) * 2007-08-30 2010-12-02 Lfb-Biotechnologies Method for purifying factor viii and von willebrand factor
US20090192076A1 (en) * 2007-12-28 2009-07-30 Baxter International Inc. Recombinant vwf formulations
US20110112023A1 (en) * 2008-07-10 2011-05-12 Gerhard Dickneite Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20120027743A1 (en) * 2008-11-03 2012-02-02 Bayer Healthcare Llc Method for the Treatment of Hemophilia
US20120027740A1 (en) * 2009-02-05 2012-02-02 Pierre Philippart Method and means for producing tissues and tissues obtained
US20110092681A1 (en) * 2009-08-20 2011-04-21 Baxter International Inc. Purification of VWF for Increased Removal of Non-Lipid Enveloped Viruses

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Designing Custom Peptides," from SIGMA Genosys, pp. 1-2. Accessed 12/16/2004. *
Advate Prescribing Information, Antihemophilic Factor (Recombinant), from Baxter, US approval date 2003. *
Berendsen HJC, "A Glimpse of the Holy Grail?" Science, 1998, 282: 642-643. *
Bradley CM, Barrick D, "Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat," J. Mol. Biol., 2002, 324: 373-386. *
Definition of derivative and analog from http://cancerweb.ncl.ac.uk/omd/about.html, pp. 1-5. Accessed 7/7/05. *
Glycine is a natural product, from www.benjamin-mills.com/chemistry/amino-acids.htm, pp. 1-4. Accessed 4/9/14. *
Lecithin is a natural product, from www.rsc.org/chemistryworld/issues/2003/july/amphiles.asp, pp. 1-7. Accessed 9/10/14. *
Mannitol is a natural product, from www.sweetenerbook.com/mannitol.html, pp. 1-3. Accessed 9/10/14. *
Ngo JT, Marks J, Karplus M, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495. *
Rudinger J, "Characteristics of the amino acids as components of a peptide hormone sequence," Peptide Hormones, JA Parsons Edition, University Park Press, June 1976, pp. 1-7. *
Schinzel R, Drueckes P, "The phosphate recognition site of Escherichia coli maltodextrin phosphorylase," FEBS, July 1991, 286(1,2): 125-128. *
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241. *
Water is natural product, from www.biology-online.org/dictionary/Water, pp. 1-3. Accessed 4/24/14. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208106B2 (en) 2010-05-26 2019-02-19 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
US11891431B2 (en) 2010-05-26 2024-02-06 Takeda Pharm Limited ceutical Company Limited Removal of serine proteases by treatment with finely divided silicon dioxide
US11136350B2 (en) 2010-05-26 2021-10-05 Takeda Pharmaceutical Company Limited Method to produce an immunoglobulin preparation with improved yield
US10875906B2 (en) 2010-05-26 2020-12-29 Baxalta Incorporated Removal of serine proteases by treatment with finely divided silicon dioxide
EP3412305A1 (de) * 2011-06-10 2018-12-12 Baxalta GmbH Behandlung einer koagulationserkrankung durch verabreichung von rekombinantem vwf
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病
WO2012171031A1 (en) * 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
AU2016202299B2 (en) * 2011-06-10 2017-07-20 Takeda Pharmaceutical Company Limited Treatment of Coagulation Disease by Administration of Recombinant VWF
US9272021B2 (en) 2011-06-10 2016-03-01 Baxalta Incorporated Treatment of coagulation disease by administration of recombinant VWF
EP3858375A1 (de) * 2011-06-10 2021-08-04 Takeda Pharmaceutical Company Limited Behandlung einer koagulationserkrankung durch verabreichung von rekombinantem vwf
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
US11529395B2 (en) 2017-07-07 2022-12-20 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US12016904B2 (en) 2017-07-07 2024-06-25 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

Also Published As

Publication number Publication date
CA2740919A1 (en) 2010-04-29
DK2349314T3 (da) 2013-05-27
US11191813B2 (en) 2021-12-07
US20160129090A1 (en) 2016-05-12
KR20110088523A (ko) 2011-08-03
NZ592704A (en) 2013-02-22
TW201509429A (zh) 2015-03-16
MX2011004247A (es) 2011-05-25
SMT201300093B (it) 2013-11-08
WO2010048275A2 (en) 2010-04-29
JP7003183B2 (ja) 2022-02-04
US10232022B2 (en) 2019-03-19
CN103919736A (zh) 2014-07-16
US20130172269A1 (en) 2013-07-04
AU2009307648B2 (en) 2015-09-24
JP2022037215A (ja) 2022-03-08
JP2016106124A (ja) 2016-06-16
CY1113869T1 (el) 2016-10-05
TW201021825A (en) 2010-06-16
PL2349314T3 (pl) 2013-07-31
KR101772674B1 (ko) 2017-09-01
TWI670072B (zh) 2019-09-01
JP2018199715A (ja) 2018-12-20
SI2349314T1 (sl) 2013-05-31
JP5781931B2 (ja) 2015-09-24
US20190142908A1 (en) 2019-05-16
BRPI0919693A2 (pt) 2020-08-11
EP2349314B1 (de) 2013-02-27
TWI593421B (zh) 2017-08-01
CN102387784B (zh) 2014-04-02
AU2009307648A1 (en) 2010-04-29
AR074054A1 (es) 2010-12-22
ES2409032T3 (es) 2013-06-24
JP2014133758A (ja) 2014-07-24
EP2601932A1 (de) 2013-06-12
JP2012506387A (ja) 2012-03-15
AU2009307648C1 (en) 2016-12-08
JP6425674B2 (ja) 2018-11-21
EP2349314A2 (de) 2011-08-03
KR20170049636A (ko) 2017-05-10
US20210315979A9 (en) 2021-10-14
AR118012A2 (es) 2021-09-08
CN102387784A (zh) 2012-03-21
JP2020143166A (ja) 2020-09-10
HRP20130414T1 (en) 2013-06-30
WO2010048275A3 (en) 2011-09-15
PT2349314E (pt) 2013-05-28
TW201722459A (zh) 2017-07-01
TWI508735B (zh) 2015-11-21
KR101953494B1 (ko) 2019-02-28

Similar Documents

Publication Publication Date Title
US11191813B2 (en) Lyophilized recombinant VWF formulations
US11191837B2 (en) Recombinant VWF formulations
JP2012506387A5 (de)
US20220257723A1 (en) Lyophilized recombinant vwf formulations
AU2017200321B2 (en) Recombinant VWF Formulations
AU2015258348A1 (en) Lyophilized Recombinant VWF Formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC.,ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHNECKER, KURT;HAIDWEGER, EVA;TURECEK, PETER;SIGNING DATES FROM 20091209 TO 20091222;REEL/FRAME:023711/0139

Owner name: BAXTER HEALTHCARE S.A.,SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHNECKER, KURT;HAIDWEGER, EVA;TURECEK, PETER;SIGNING DATES FROM 20091209 TO 20091222;REEL/FRAME:023711/0139

AS Assignment

Owner name: BAXALTA INCORPORATED, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER INTERNATIONAL INC.;REEL/FRAME:036372/0001

Effective date: 20150811

Owner name: BAXALTA GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER INTERNATIONAL INC.;REEL/FRAME:036372/0001

Effective date: 20150811

Owner name: BAXALTA GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER HEALTHCARE SA;REEL/FRAME:036376/0572

Effective date: 20150811

Owner name: BAXALTA INCORPORATED, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER HEALTHCARE SA;REEL/FRAME:036376/0572

Effective date: 20150811

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION